Alessa Therapeutics News and Activities

Alessa Therapeutics is owned by Mission BioCapital. Mission BioCapital has a direct presence in 2 countries.

Mission BioCapital has 20 subsidiaries including Alessa Therapeutics, Avvio Medical and Avvio Medical AMEA.

They are in:

• Biotechnology76%
• Healthcare10%
• Other14%

Acquisition, funding and merger involving Mission BioCapital.

• Mission BioCapital has just announced a $134 Million fundraising (posted on September 28 2025).

View the org chart displaying its 12 main executives

Most searched biographies at Alessa Therapeutics

• Cam Gallagher, Chief Executive Officer and President
• Annie Mitsak, Director
• Richard Lim, Director

Popular executive movements at Alessa Therapeutics

• Neal Shore has joined the company as Co-Chairman of the Board  (posted on May 26 2026).
• Peter Carroll has joined the company as Co-Chairman of the Board  (posted on May 26 2026).

Create your alert
to follow the executive moves at Alessa Therapeutics.

Mission BioCapital has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Ona Therapeutics has just announced a $87 Million fundraising (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Alessa Therapeutics

• Alessa Therapeutics Announces Enolen Phase 1 Study Presentation Receives “Best Poster” Award at the American Urological Association Annual Meeting | Alessa Therapeutics
• Alessa Therapeutics Appoints Dr. Peter Carroll and Dr. Neal Shore to Lead Clinical Advisory Board | Alessa Therapeutics
• Alessa Therapeutics Announces Positive Preliminary Safety and Efficacy Data from Enolen Phase 1 Trial | Alessa Therapeutics
• Latest Press Releases & News - Alessa Therapeutics

Social media about Alessa Therapeutics

• Alessa Therapeutics on Wikipedia, Google News & Yahoo Finance
• Alessa Therapeutics on LinkedIn, X (Twitter) & YouTube